Home › Trial NCT00712790
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
- Trial IDNCT00712790
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorSingapore Clinical Research Institute
- Enrollment35
- Start date2008-06
- ConditionsHepatocellular Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.